GLOW – BPC-157/GHK-Cu/TB-500 Blend Often referred to as the “Glow Stack” or “Glow Blend” , this powerful combination of three regenerative peptides synergistically targets whole-body tissue repair, joint recovery, and cellular rejuvenation. The formulation typically comes in a single lyophilized vial featuring BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (50 to 70 mg). [1, 2, 3, 4, 5]
How the Peptides Work Together
- BPC-157 (Body Protection Compound 157): Originally derived from gastric juice, this peptide supports the healing of tendons, ligaments, and the gut. It operates by promoting angiogenesis (the formation of new blood vessels) and reducing inflammation. [1, 2]
- TB-500 (Thymosin Beta-4): This synthetic fraction of a naturally occurring protein enhances cellular migration. It works systemically to repair muscles, joints, and connective tissue, while also improving hair and skin quality. [1, 2, 3]
- GHK-Cu (Copper Peptide): A copper-binding tripeptide that is a staple for skin and hair health. It stimulates collagen production, acts as a potent antioxidant, and promotes faster wound healing. [1, 2, 3] GLOW – BPC-157/GHK-Cu/TB-500 Blend
Common Research Ratios & Dosing
The “Glow Blend” is typically reconstituted with Bacteriostatic Water. The ratio of the blend will dictate your daily or weekly dosage volume. [1]
A common dosing guide for a 90 mg or 70 mg vial generally targets:
Potential Benefits
- Accelerated Recovery: Speeds up the healing of muscle tears, tendon injuries, and joint inflammation.
- Anti-Aging & Rejuvenation: Increases collagen synthesis and improves skin elasticity, tone, and texture.
- Hair & Scalp Health: Promotes follicle stimulation and supports hair thickness.
- Systemic Healing: Reduces whole-body oxidative stress and supports gastrointestinal health. [1, 2, 3, 4, 5]
Could you tell me what your primary goals are for using this stack (eg, recovering from an injury, anti-aging, or hair/skin health) so I can help you narrow down an appropriate research protocol ?
Reviews
There are no reviews yet.